Fusion Antibodies and ISCA Diagnostic Successfully Develop Humanized Antibody for Invasive Pulmonary Aspergillosis

Share Article

Fusion Antibodies and ISCA diagnostics are today announcing that they have successfully developed a humanized version of ISCA Diagnostic’s Aspergillus-specific monoclonal antibody JF5. The project has taken place over the past 10 months and today marks its successful completion.

Fusion Antibodies ISCA Diagnostics JF5 ELISA

Graph showing binding curves of humanized vs parental antibody. JF5 is the parental murine antibody. IB3, 7C4 and 2B10 are stable clones expressing humanized antibodies

We are delighted to have worked with Chris Thornton and the team at ISCA Diagnostics

UK based contract research organisation Fusion Antibodies and UK medical diagnostics company ISCA Diagnostics, have today announced the successful completion of the humanization of the Aspergillus-specific monoclonal antibody JF5. The project was completed ahead of schedule and with outstanding results.

The JF5 humanization project is the most recent in a series of successful projects for Fusion Antibodies and is a case study example of the robust nature of Fusion Antibodies’ CDRx humanization platform. Fusion Antibodies have been able to prove that is CDRx Humanization platform maintains the binding affinity of the parental JF5 antibody. As the ELISA data shows, high titres of the three clones are displayed against the target mannoprotein antigen when compared with mouse antibody from the parent hybridoma JF5, with target recognition maintained at the picogram/ml level.

Paul Kerr, Managing Director at Fusion Antibodies commented: “We are delighted to have worked with Chris Thornton and the team at ISCA Diagnostics and are excited for the future of the humanized JF5 antibody”. Chris Thornton of ISCA Diagnostics added: “The humanized antibody will now enter cGMP production for use as a theranostic agent for diagnosis and therapy of invasive pulmonary aspergillosis in humans. The production by Fusion Antibodies of a highly sensitive and specific humanised version of the JF5 antibody for ISCA places us at the forefront of the fight against this devastating disease of immunocompromised patients. This ground breaking work opens up highly novel opportunities for early detection and treatment of the disease.” Fusion Antibodies will now transfer all materials to ISCA Diagnostics for commencement of work package 2 in the MATHIAS programme.

About Fusion Antibodies
Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With 12+ years of experience in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide Royalty Free Antibody Humanization of Monoclonal Antibodies and using their next generation in silico CDRx™ technology, they have modernized the traditional CDR grafting technique. Fully humanized monoclonal antibodies are an essential step in the progression of therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Visit their website at http://www.fusionantibodies.com to find our more

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrew Glover
Follow >
Fusion Antibodies
Like >
Fusion Antibodies Ltd

Follow us on
Visit website